Skip to main content
Top
Published in: International Journal of Hematology 5/2017

01-11-2017 | Original Article

CD34-negative hematopoietic stem cells show distinct expression profiles of homing molecules that limit engraftment in mice and sheep

Authors: Tomoyuki Abe, Yoshikazu Matsuoka, Yoshikazu Nagao, Yoshiaki Sonoda, Yutaka Hanazono

Published in: International Journal of Hematology | Issue 5/2017

Login to get access

Abstract

We and others have reported that human hematopoietic stem cells (HSCs) are also present in the CD34-negative (CD34) fraction of human cord blood (CB). Here, we examined the hematopoietic engraftment potential of 13 or 18 lineage-negative (13Lin or 18Lin) CD34+/− cells from human CB in mice and sheep. Both 13Lin and 18Lin CD34+ cells efficiently engrafted in mice irrespective of transplantation route, be it by tail-vein injection (TVI) or by intra-bone marrow injection (IBMI). These cells also engrafted in sheep after in utero fetal intra-hepatic injection (IHI). In contrast, neither 13Lin nor 18Lin CD34 cells engrafted in either mice or sheep when transplanted by regular routes (i.e., TVI and fetal IHI, respectively), although both 13Lin and 18Lin CD34 cells engrafted in mice when transplanted by IBMI and exhibited multilineage reconstitution ability. Thus, the homing ability of CD34 HSCs is significantly more limited than that of CD34+ HSCs. As for 18Lin, CD34 HSCs are characterized by low expression of the tetraspanin CD9, which promotes homing, and high expression of the peptidase CD26, which inhibits homing. This unique expression pattern homing-related molecules on CD34 HSCs could thus explain in part their reduced ability to home to the BM niche.
Literature
1.
go back to reference Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood. 1996;87:1–13.PubMed Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood. 1996;87:1–13.PubMed
2.
go back to reference Civin CI, Trischmann T, Kadan NS, Davis J, Noga S, Cohen K, et al. Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol. 1996;14:2224–33.CrossRefPubMed Civin CI, Trischmann T, Kadan NS, Davis J, Noga S, Cohen K, et al. Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol. 1996;14:2224–33.CrossRefPubMed
3.
go back to reference Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci USA. 2002;99:413–8.CrossRefPubMedPubMedCentral Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci USA. 2002;99:413–8.CrossRefPubMedPubMedCentral
4.
go back to reference Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic cell. Science. 1996;273:242e5.CrossRef Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic cell. Science. 1996;273:242e5.CrossRef
5.
go back to reference Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med. 1998;4:1038–45.CrossRefPubMed Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med. 1998;4:1038–45.CrossRefPubMed
6.
go back to reference Wang J, Kimura T, Asada R, Harada S, Yokota S, Kawamoto Y, et al. SCID-repopulating cell activity of human cord blood-derived CD34− cells assured by intra-bone marrow injection. Blood. 2003;101:2924–31.CrossRefPubMed Wang J, Kimura T, Asada R, Harada S, Yokota S, Kawamoto Y, et al. SCID-repopulating cell activity of human cord blood-derived CD34 cells assured by intra-bone marrow injection. Blood. 2003;101:2924–31.CrossRefPubMed
7.
go back to reference Kimura T, Wang J, Matsui K, Imai S, Yokoyama S, Nishikawa M, et al. Proliferative and migratory potentials of human cord blood-derived CD34- severe combined immunodeficiency repopulating cells that retain secondary reconstituting capacity. Int J Hematol. 2004;79:328–33.CrossRefPubMed Kimura T, Wang J, Matsui K, Imai S, Yokoyama S, Nishikawa M, et al. Proliferative and migratory potentials of human cord blood-derived CD34- severe combined immunodeficiency repopulating cells that retain secondary reconstituting capacity. Int J Hematol. 2004;79:328–33.CrossRefPubMed
8.
go back to reference Ando K. Human CD34- hematopoietic stem cells: basic features and clinical relevance. Int J Hematol. 2002;75:370–5.CrossRefPubMed Ando K. Human CD34- hematopoietic stem cells: basic features and clinical relevance. Int J Hematol. 2002;75:370–5.CrossRefPubMed
9.
go back to reference Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA. 1997;94:5320–5.CrossRefPubMedPubMedCentral Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA. 1997;94:5320–5.CrossRefPubMedPubMedCentral
10.
go back to reference Greiner DL, Hesselton RA, Shultz LD. SCID mouse models of human stem cell engraftment. Stem Cells. 1998;16:166–77.CrossRefPubMed Greiner DL, Hesselton RA, Shultz LD. SCID mouse models of human stem cell engraftment. Stem Cells. 1998;16:166–77.CrossRefPubMed
11.
go back to reference Civin CI, Almeida-Porada G, Lee MJ, Olweus J, Terstappen LW, Zanjani ED. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood. 1996;88:4102–9.PubMed Civin CI, Almeida-Porada G, Lee MJ, Olweus J, Terstappen LW, Zanjani ED. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood. 1996;88:4102–9.PubMed
12.
go back to reference Abe T, Masuda S, Ban H, Hayashi S, Ueda Y, Inoue M, et al. Ex vivo expansion of human HSCs with Sendai virus vector expressing HoxB4 assessed by sheep in utero transplantation. Exp Hematol. 2011;39:47–54.CrossRefPubMed Abe T, Masuda S, Ban H, Hayashi S, Ueda Y, Inoue M, et al. Ex vivo expansion of human HSCs with Sendai virus vector expressing HoxB4 assessed by sheep in utero transplantation. Exp Hematol. 2011;39:47–54.CrossRefPubMed
13.
14.
go back to reference Ishii M, Matsuoka Y, Sasaki Y, Nakatsuka R, Takahashi M, Nakamoto T, et al. Development of a high-resolution purification method for precise functional characterization of primitive human cord blood-derived CD34-negative SCID-repopulating cells. Exp Hematol. 2011;39:203–13.CrossRefPubMed Ishii M, Matsuoka Y, Sasaki Y, Nakatsuka R, Takahashi M, Nakamoto T, et al. Development of a high-resolution purification method for precise functional characterization of primitive human cord blood-derived CD34-negative SCID-repopulating cells. Exp Hematol. 2011;39:203–13.CrossRefPubMed
15.
go back to reference Kimura T, Matsuoka Y, Murakami M, Kimura T, Takahashi M, Nakamoto T, et al. In vivo dynamics of human cord blood-derived CD34− SCID-repopulating cells using intra-bone marrow injection. Leukemia. 2010;24:162–8.CrossRefPubMed Kimura T, Matsuoka Y, Murakami M, Kimura T, Takahashi M, Nakamoto T, et al. In vivo dynamics of human cord blood-derived CD34 SCID-repopulating cells using intra-bone marrow injection. Leukemia. 2010;24:162–8.CrossRefPubMed
16.
go back to reference Abe T, Masuda S, Tanaka Y, Nitta S, Kitano Y, Hayashi S, et al. Maternal administration of busulfan before in utero transplantation of human hematopoietic stem cells enhances engraftments in sheep. Exp Hematol. 2012;40:436–44.CrossRefPubMed Abe T, Masuda S, Tanaka Y, Nitta S, Kitano Y, Hayashi S, et al. Maternal administration of busulfan before in utero transplantation of human hematopoietic stem cells enhances engraftments in sheep. Exp Hematol. 2012;40:436–44.CrossRefPubMed
17.
go back to reference Nagao Y, Abe T, Hasegawa H, Tanaka Y, Sasaki K, Kitano Y, et al. Improved efficacy and safety of in utero cell transplantation in sheep using an ultrasound-guided method. Cloning Stem Cells. 2009;11:281–5.CrossRefPubMed Nagao Y, Abe T, Hasegawa H, Tanaka Y, Sasaki K, Kitano Y, et al. Improved efficacy and safety of in utero cell transplantation in sheep using an ultrasound-guided method. Cloning Stem Cells. 2009;11:281–5.CrossRefPubMed
18.
go back to reference Tanaka Y, Masuda S, Abe T, Hayashi S, Kitano Y, Nagao Y, et al. Intravascular route is not superior to an intraperitoneal route for in utero transplantation of human hematopoietic stem cells and engraftment in sheep. Transplantation. 2010;90:462–3.CrossRefPubMed Tanaka Y, Masuda S, Abe T, Hayashi S, Kitano Y, Nagao Y, et al. Intravascular route is not superior to an intraperitoneal route for in utero transplantation of human hematopoietic stem cells and engraftment in sheep. Transplantation. 2010;90:462–3.CrossRefPubMed
19.
go back to reference Leung KT, Chan KY, Ng PC, Lau TK, Chiu WM, Tsang KS, et al. The tetraspanin CD9 regulates migration, adhesion, and homing of human cord blood CD34+ hematopoietic stem and progenitor cells. Blood. 2011;117:1840–50.CrossRefPubMed Leung KT, Chan KY, Ng PC, Lau TK, Chiu WM, Tsang KS, et al. The tetraspanin CD9 regulates migration, adhesion, and homing of human cord blood CD34+ hematopoietic stem and progenitor cells. Blood. 2011;117:1840–50.CrossRefPubMed
20.
go back to reference Christopherson KW, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004;305:1000–3.CrossRefPubMed Christopherson KW, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004;305:1000–3.CrossRefPubMed
21.
go back to reference Zanjani ED, Almeida-Porada G, Livingston AG, Porada CD, Ogawa M. Engraftment and multilineage expression of human bone marrow CD34- cells in vivo. Ann N Y Acad Sci. 1999;872:220–31.CrossRefPubMed Zanjani ED, Almeida-Porada G, Livingston AG, Porada CD, Ogawa M. Engraftment and multilineage expression of human bone marrow CD34- cells in vivo. Ann N Y Acad Sci. 1999;872:220–31.CrossRefPubMed
22.
go back to reference Zanjani ED, Almeida-Porada G, Livingston AG, Flake AW, Ogawa M. Human bone marrow CD34− cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. Exp Hematol. 1998;26:353–60.PubMed Zanjani ED, Almeida-Porada G, Livingston AG, Flake AW, Ogawa M. Human bone marrow CD34− cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. Exp Hematol. 1998;26:353–60.PubMed
23.
go back to reference Takahashi M, Matsuoka Y, Sumide K, Nakatsuka R, Fujioka T, Kohno H, et al. CD133 is a positive marker for a distinct class of primitive human cord blood-derived CD34-negative hematopoietic stem cells. Leukemia. 2014;28:1308–15.CrossRefPubMed Takahashi M, Matsuoka Y, Sumide K, Nakatsuka R, Fujioka T, Kohno H, et al. CD133 is a positive marker for a distinct class of primitive human cord blood-derived CD34-negative hematopoietic stem cells. Leukemia. 2014;28:1308–15.CrossRefPubMed
24.
go back to reference Matsuoka Y, Sumide K, Kawamura H, Nakatsuka R, Fujioka T, Sonoda Y. GPI-80 expression highly purifies human cord blood-derived primitive CD34-negative hematopoietic stem cells. Blood. 2016;128:2258–60.CrossRefPubMed Matsuoka Y, Sumide K, Kawamura H, Nakatsuka R, Fujioka T, Sonoda Y. GPI-80 expression highly purifies human cord blood-derived primitive CD34-negative hematopoietic stem cells. Blood. 2016;128:2258–60.CrossRefPubMed
25.
go back to reference Kollet O, Petit I, Kahn J, Samira S, Dar A, Peled A, et al. Human CD34+ CXCR4− sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood. 2002;100:2778–86.CrossRefPubMed Kollet O, Petit I, Kahn J, Samira S, Dar A, Peled A, et al. Human CD34+ CXCR4− sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood. 2002;100:2778–86.CrossRefPubMed
26.
go back to reference Masuda S, Ageyama N, Shibata H, Obara Y, Ikeda T, Takeuchi K, et al. Cotransplantation with MSCs improves engraftment of HSCs after autologous intra-bone marrow transplantation in nonhuman primates. Exp Hematol. 2009;37:1250–7.CrossRefPubMed Masuda S, Ageyama N, Shibata H, Obara Y, Ikeda T, Takeuchi K, et al. Cotransplantation with MSCs improves engraftment of HSCs after autologous intra-bone marrow transplantation in nonhuman primates. Exp Hematol. 2009;37:1250–7.CrossRefPubMed
27.
go back to reference Matsuoka Y, Nakatsuka R, Sumide K, Kawamura H, Takahashi M, Fujioka T, et al. Prospectively isolated human bone marrow cell-derived MSCs support primitive human CD34-negative hematopoietic stem cells. Stem Cells. 2015;33:1554–65.CrossRefPubMed Matsuoka Y, Nakatsuka R, Sumide K, Kawamura H, Takahashi M, Fujioka T, et al. Prospectively isolated human bone marrow cell-derived MSCs support primitive human CD34-negative hematopoietic stem cells. Stem Cells. 2015;33:1554–65.CrossRefPubMed
28.
go back to reference Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. Int J Hematol. 2017;105:549–57.CrossRefPubMed Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. Int J Hematol. 2017;105:549–57.CrossRefPubMed
Metadata
Title
CD34-negative hematopoietic stem cells show distinct expression profiles of homing molecules that limit engraftment in mice and sheep
Authors
Tomoyuki Abe
Yoshikazu Matsuoka
Yoshikazu Nagao
Yoshiaki Sonoda
Yutaka Hanazono
Publication date
01-11-2017
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2017
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2290-5

Other articles of this Issue 5/2017

International Journal of Hematology 5/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine